Marcel Arnold: Honoraria for lecturs: Astra Zeneca, Bayer, Novartis, Sanofi, Scientific advisory boards: Amgen, BMS/Pfizer, Novo Nordisk, Daiichi Sankyo, Medtronic, Novartis, Grants Swiss National Science Foundation Poster session I - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.10 - ESUS/CRYPTOGENIC STROKE P326 - ESOC25-2305 A MACHINE LEARNING BASED APPROACH TO IDENTIFY ESUS ETIOLOGIES Adriano Bonura 1 , Claudia Meza 1 , Jesus Juega 1 , Marian Muchada 1 , Alvaro Garcia-Tornel 1 , Federica Rizzo 1 , Renato Simonetti 1 , Marta Olive 1 , Marc Rodrigo 1 , Noelia Rodriguez-Villatoro 1 , David Rodriguez Luna 1 , Marta Rubiera 1 , Carlos Molina 1 , Jorge Pagola 1 Vall dHebron, Stroke Unit, Barcelona, Spain Background and Aims: Embolic Stroke of Undetermined Source (ESUS) accounts for about one-quarter of all ischemic strokes and poses a notable challenge in modern vascular neurology due to its high recurrence rate and diverse underlying mechanisms

Sensitive or Inflamed Skin Its anti-inflammatory action soothes irritated skin and promotes barrier repair, making it ideal for sensitive skin types
Safety Profile Summary A formal preclinical safety evaluation published in 2020 by Xu et al
394 P2Y6R, which also belongs to the purinergic receptor family, is involved in inflammatory responses and immune regulation by regulating the signaling of extracellular nucleotides (e.g., UDPs) and effectively ameliorates the effects of DSS-induced ulcerative colitis in mice
To alleviate symptoms, painkillers or antispasmodics can be additionally introduced